TMAO: how gut microbiota contributes to heart failure

Area of Science:

• Microbiology
• Cardiovascular Medicine
• Metabolomics

Background:

• Gut microbiota dysbiosis is increasingly linked to cardiovascular diseases.
• In heart failure (HF), intestinal barrier dysfunction promotes bacterial translocation and inflammation.

Purpose of the Study:

• To review the role of gut microbiota-derived metabolites in HF pathogenesis.
• To highlight trimethylamine N-oxide (TMAO) as a key metabolite in HF.
• To explore the gut-TMAO-HF axis as a therapeutic target.

Main Methods:

• Literature review focusing on gut microbiota, metabolites, and HF.
• Analysis of TMAO's role in HF pathology and as a biomarker.
• Discussion of current research and future directions.

Main Results:

• Gut microbiota metabolites, particularly TMAO, contribute to HF progression.
• TMAO can serve as an early warning marker for HF risk and disease advancement.
• The gut-TMAO-HF axis presents a novel therapeutic avenue.

Conclusions:

• Gut microbiota modulation and targeting TMAO production are potential strategies for HF management.
• Further research is needed to fully elucidate the gut-TMAO-HF axis and its therapeutic implications.